原发性腹膜后肉瘤:专科肉瘤中心与非专科中心生存结局比较
基于英格兰国家癌症登记数据,纳入2013至2018年诊断的原发性腹膜后肉瘤患者1878例,其中1120例(60%)在诊断后12个月内接受手术。比较在高容量专科肉瘤中心、低容量专科肉瘤中心及非专科中心手术患者的生存,发现高容量专科中心患者总生存显著优于另两类中心。
要点
- 1878例原发性腹膜后肉瘤患者中,1120例(60%)在诊断后12个月内接受手术。
- 手术患者中847例(76%)在专科肉瘤中心手术,其中高容量中心432例(51%)、低容量中心415例(49%)。
- 校正患者和治疗相关因素后,高容量专科中心较低容量专科中心总生存显著更长,校正风险比0.78(95%CI 0.62-0.96,p<0.05)。
核心结论
- 在高容量专科肉瘤中心接受手术的原发性腹膜后肉瘤患者,生存结局显著优于在非专科中心和低容量专科肉瘤中心治疗的患者。
研究设计与样本
- 从NHS Digital国家癌症注册与分析服务提取2013年至2018年诊断的原发性腹膜后肉瘤患者数据,比较不同中心类型的诊断路径、治疗和生存结局,并进行单因素和多因素分析。
主要发现
- 1878例患者中,1120例(60%)在诊断后12个月内接受手术,其中847例(76%)在专科肉瘤中心手术,高容量中心432例(51%)、低容量中心415例(49%)。
- 非专科中心手术患者1年和5年估算总生存率分别为70.6%(95%CI 64.8-75.7)和42.0%(95%CI 35.9-47.9)。
- 低容量专科肉瘤中心手术患者1年和5年估算总生存率分别为85.0%(95%CI 81.1-88.1)和51.7%(95%CI 46.6-56.6),与非专科中心相比p<0.01。
- 高容量专科肉瘤中心手术患者1年和5年估算总生存率分别为87.4%(95%CI 83.9-90.2)和62.8%(95%CI 57.9-67.4),与非专科中心相比p<0.01。
- 校正患者和治疗相关因素后,高容量专科肉瘤中心较低容量专科肉瘤中心总生存显著更长,校正风险比0.78(95%CI 0.62-0.96,p<0.05)。
临床怎么用
- 共识指南指出原发性腹膜后肉瘤患者应在专科肉瘤中心接受管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Consensus guidelines outline that patients with primary retroperitoneal sarcoma (RPS) should be managed within specialist sarcoma centres (SSC). There is, however, a paucity of population-based data detailing incidence and outcomes in these patients. Hence, we aimed to evaluate patterns of care among RPS patients in England and compare outcomes for those undergoing surgery in high-volume specialist sarcoma centres (HV-SSC), low-volume SSC (LV-SSC), and non-SSC (N-SSC). METHODS: Data on patients diagnosed with primary RPS between 2013 and 2018 were extracted from NHS Digital's National Cancer Registration and Analysis Service using the national cancer registration dataset. Diagnostic pathways, treatment, and survival outcomes were compared between HV-SSC, LV-SSC, and N-SSC. Uni- and multivariate analyses were calculated. RESULTS: Of 1878 patients diagnosed with RPS, 1120 (60%) underwent surgery within 12 months of diagnosis, with 847 (76%) operated on at SSC; of these, 432 patients (51%) were operated on in HV-SSC, and 415 (49%) in LV-SSC. One- and 5-year estimated overall survival (OS) rates for patients undergoing surgery in N-SSC were 70.6% (95% confidence interval [CI]: 64.8-75.7) and 42.0% (CI: 35.9-47.9), compared to 85.0% (CI: 81.1-88.1) and 51.7% (CI: 46.6-56.6) in LV-SSC (p < 0.01), and 87.4% (CI: 83.9-90.2) and 62.8% (CI: 57.9-67.4) in HV-SSC, (p < 0.01). After adjusting for patient- and treatment-related factors, patients treated in HV-SSC were found to have significantly longer OS than those treated at LV-SSC, with an adjusted hazard ratio of 0.78 (CI: 0.62-0.96, p < 0.05). CONCLUSION: Patients with RPS undergoing surgery in HV-SSC have significantly better survival outcomes than those treated in N-SSC and L-SSC.
引用
- Tirotta F, Bacon A, Collins S, et al. Primary retroperitoneal sarcoma: A comparison of survival outcomes in specialist and non-specialist sarcoma centres. Eur J Cancer. 2023. PMID: 37178646. doi:10.1016/j.ejca.2023.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。